. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: Breast Cancer Res Treat. 2019 Oct 26;179(2):337–347. doi: 10.1007/s10549-019-05473-9

Table 1. Combination indices of Copanlisib with EPHA2 (ALW-41–27 and dasatinib) or CEPNE (GSK923295) chemical knockdown using the Chou-Talalay method.

Effective dose for 50% or 75% inhibition shown as ED50 and ED75, respectively. Blue indicates synergy, orange indicates antagonism. NA denoted when an EC50 curve could not be generated for the companion drug alone. Cells are ordered with Copanlisib-sensitive cell lines at the top and Copanlisib-insensitive cell lines at the bottom.

	ALW-II-41-27 (EPHA2)		Dasatinib (EPHA2)		GSK923295 (CENPE)
Cell Line:	ED₅₀	ED₇₅	ED₅₀	ED₇₅	ED₅₀	ED₇₅
SUM102	0.78	0.58	0.22	0.24	0.73	0.69
MDA-MB-453	0.42	0.31	NA	NA	0.64	0.67
BT20	0.61	0.32	0.33	0.45	1.2	0.86
SUM185	0.63	0.37	NA	NA	0.97	0.80
Hs578T	0.39	0.33	0.21	0.19	0.34	0.61
HCC1937	0.63	0.28	0.30	0.31	0.37	0.22
MDA-MB-436	19	0.35	0.40	0.39	62	1.5